1,2,3,5-四氢螺[4H-1-苯并氮杂卓-4,1’’-[2]环戊烯]-3’’-甲酸 | 813426-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 1,2,3,5-四氢螺[4H-1-苯并氮杂卓-4,1’’-[2]环戊烯]-3’’-甲酸
• 英文名称: 1,2,3,5-tetrahydrospiro[4H-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
• 英文别名: 1,2,3,5-Tetrahydrospiro[benzo[b]azepine-4,1-cyclopent[2]ene]-3'-carboxylic acid；spiro[1,2,3,5-tetrahydro-1-benzazepine-4,3'-cyclopentene]-1'-carboxylic acid
• CAS: 813426-13-0
• 化学式: C₁₅H₁₇NO₂
• 分子量: 243.305
• InChiKey: UJGOKTVNHDTZTN-UHFFFAOYSA-N

物化性质

• 密度：
  1.24

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,2,3,5-四氢螺[4H-1-苯并氮杂卓-4,1’’-[2]环戊烯]-3’’-甲酸 、 乙醇 在 硫酸 作用下， 以94%的产率得到Ethyl spiro[1,2,3,5-tetrahydro-1-benzazepine-4,3'-cyclopentene]-1'-carboxylate
  参考文献：
  名称：

  Next-generation spirobenzazepines: Identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies

  摘要：

  We have continued to explore spirobenzazepines as vasopressin receptor antagonists to follow up on RWJ-339489 (2), which had advanced into preclinical development. Further structural modi. cations were pursued to find a suitable backup compound for human clinical studies. Thus, we identified carboxylic acid derivative 3 (RWJ-676070; JNJ-17158063) as a potent, balanced vasopressin V-1a/V-2 receptor antagonist with favorable properties for clinical development. Compound 3 is currently undergoing human clinical investigation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.059
• 作为产物：
  描述：

  Ethyl 1,2,3,5-tetrahydro-2'-hydroxy-1-[(4-methylphenyl)sulfonyl]-spiro[4H-1-benzazepine-4,1'-cyclopentane]-3'-carboxylate 在 硫酸 、 溶剂黄146 、 氢氧化钾 作用下， 以 水 为溶剂， 反应 24.0h， 生成 1,2,3,5-四氢螺[4H-1-苯并氮杂卓-4,1’’-[2]环戊烯]-3’’-甲酸
  参考文献：
  名称：

  Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives

  摘要：

  新型螺合苯并氮杂环庚烷化合物，用于制备非肽替代螺合苯并氮杂环庚烷衍生物的新工艺，以及用于制备这类衍生物制备中间体的新工艺。用于制备非肽替代螺合苯并氮杂环庚烷衍生物的新中间体。

  公开号：

  US20040259857A1

文献信息

• PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES
  申请人：Deng Xiaohu

  公开号：US20090105220A1

  公开（公告）日：2009-04-23

  Novel spirobenzoazepine compounds, novel processes for the preparation of nonpeptide substituted spirobenzoazepine derivatives, and novel processes for the preparation of intermediates in the preparation of such derivatives. Novel intermediates in the preparation of nonpeptide substituted spirobenzoazepine derivatives.

  新型螺苯并氮杂环化合物，制备非肽取代螺苯并氮杂环衍生物的新型方法，以及制备此类衍生物的中间体的新型方法。制备非肽取代螺苯并氮杂环衍生物的新型中间体。
• NOVEL SOLID FORMS OF (4R)-1-[4-(2-CHLORO-5-FLUOROBENZOYL)AMINO-3-METHOXYBENZOYL]-1,2,3,5-TETRAHYDRO-SPIRO[4H-1-BENZAZEPINE-4,1'-[2]CYCLOPENTENE]-3'-CARBOXYLIC ACID
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP1984342A2

  公开（公告）日：2008-10-29
• [EN] PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES<br/>[FR] PROCESSUS DE PREPARATION DE DERIVES DE SPIROBENZOAZEPINE SUBSTITUES NON PEPTIDIQUES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005000819A1

  公开（公告）日：2005-01-06

  Novel spirobenzoazepine compounds, novel processes for the preparation of nonpeptide substituted spirobenzoazepine dervatives, and novel processes for the preparation of intermediates in the preparation of such derivatives. Novel intermediates in the preparation of nonpeptide substituted spirobenzoazepine derviatives.
• [EN] NOVEL SOLID FORMS OF (4R)-1-[4-(2-CHLORO-5-FLUOROBENZOYL)AMINO-3-METHOXYBENZOYL]-1,2,3,5-TETRAHYDRO-SPIRO[4H-1-BENZAZEPINE-4,1'-[2]CYCLOPENTENE]-3'-CARBOXYLIC ACID<br/>[FR] FORMES SOLIDES ATYPIQUES D'ACIDE CARBOXYLIQUE (4R)-1-[4-(2-CHLORO-5-FLUOROBENZOYL)AMINO-3-METHOXYBENZOYL]-1,2,3,5-TETRAHYDRO-SPIRO[4H-1-BENZAZEPINE-4,1'-[2]CYCLOPENTENE]-3'
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2007084591A2

  公开（公告）日：2007-07-26

  [EN] The present invention relates to novel solid forms of (4R)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4H-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid (formula (I)) useful for treating and/or preventing conditions such as diabetic nephropathy, renal disease, renal failure and congestive heart failure.
  [FR] La présente invention concerne des formes solides atypiques d'acide carboxylique (4R)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-méthoxybenzoyl]-1,2,3,5-tétrahydro-spiro[4H-1-benzazépine-4,1'-[2]cyclopentène]-3'(formula (I)) utiles dans le traitement et/ou la prévention de conditions telles qu'une néphropathie diabétique, une maladie rénale, une insuffisance rénale et une insuffisance cardiaque congestive.
• Next-generation spirobenzazepines: Identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies
  作者：Min Amy Xiang、Philip J. Rybczynski、Mona Patel、Robert H. Chen、David F. McComsey、Han-Cheng Zhang、Joseph W. Gunnet、Richard Look、Yuanping Wang、Lisa K. Minor、H. Marlon Zhong、Frank J. Villani、Keith T. Demarest、Bruce P. Damiano、Bruce E. Maryanoff

  DOI：10.1016/j.bmcl.2007.09.059

  日期：2007.12

  We have continued to explore spirobenzazepines as vasopressin receptor antagonists to follow up on RWJ-339489 (2), which had advanced into preclinical development. Further structural modi. cations were pursued to find a suitable backup compound for human clinical studies. Thus, we identified carboxylic acid derivative 3 (RWJ-676070; JNJ-17158063) as a potent, balanced vasopressin V-1a/V-2 receptor antagonist with favorable properties for clinical development. Compound 3 is currently undergoing human clinical investigation. (c) 2007 Elsevier Ltd. All rights reserved.